European Event-Driven Analyst

Jesus Rodriguez Aguilar

Jesús is an Insight Provider (Event-driven) on the Smartkarma network, where he looks across sectors at opportunities arising from securities mispricing (both credit and equity), share classes, bid announcements, prospective bids, and special situations. He has served as Economic and Business Advisor at the Spanish Congress in Madrid. Prior to that, he has worked in the City of London: as a Credit Analyst at Bloomberg; Event-driven associate at former boutique European Research; and doubled as Special Situations and Equity-linked VP (convertible bonds) at Merrill Lynch. Jesús has an MBA from the London Business School, a BA (Hons.) degree in Economics from the Complutense University in Madrid, and a BA (Hons.) in Law from U.N.E.D., also in Madrid.

GSK (GSK.L/​​​​GSK.N):  Bluebell Capital Partners Aligns with Elliott

GSK (GSK.L/​​​GSK.N): Revisiting Elliott’s Letter and What Remains Unanswered

GSK (GSK.L/​​GSK.N) Fails to Impress, in Their Response to Elliot

Event-Driven

<ul>
<li>GSK has rejected Unilever's approaches (last at £50 billion) but leaked it would be ready to accept an offer around £60 billion (a whopping c. 65% of Unilever's market capitalisation).</li>
<li>The deal would be transformational and Unilever's management see it as the way forward to revive the company's performance and the share price.</li>
<li>
Ballsy, but doable, with a positive impact on results from FY2024, but negative impact on leverage at 4.9x. I believe that Unilever may make a further approach.</li>
</ul>


GSK has rejected Unilever's approaches (last at £50 billion) but leaked it would be ready to accept an offer around £60 billion (a whopping c. 65% of Unilever's market capitalisation).
The deal would be transformational and Unilever's management see it as the way forward to revive the company's performance and the share price.

Ballsy, but doable, with a positive impact on results from FY2024, but negative impact on leverage at 4.9x. I believe that Unilever may make a further approach.


Unilever/GSK Heathcare: Ballsy, but Doable

GlaxoSmithKline PLC

Unilever/GSK Heathcare: Ballsy, but Doable